[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"intravitreal-injections\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:intravitreal-injections":30},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,52,82],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":31,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":41,"lastUpdatePostDateStruct":42,"startDateStruct":45,"completionDateStruct":47,"leadSponsor":49,"locationsCount":4},"100629963","speculum-free-intravitreal-injection-using-cotton-tipped-applicator-retraction-a-randomized-trial-of-pain-procedure-time-patient-satisfaction-and-safety-100629963",false,"NCT07481500","Speculum-Free Intravitreal Injection Using Cotton-Tipped Applicator Retraction: A Randomized Trial of Pain, Procedure Time, Patient Satisfaction, and Safety","Speculum-Free Intravitreal Injection Using Cotton-Tipped Applicator Retraction: A Randomized Controlled Trial Comparing Pain Perception, Procedure Duration, Patient Satisfaction, and Safety Between Eyelid Speculum and Cotton-Tipped Applicator Retraction Techniques","IVI-RETRACT","Inclusion Criteria:\n\n1. Age 18 years or older\n2. Diagnosed with neovascular age-related macular degeneration (nAMD), diabetic macular edema (DME), or retinal vein occlusion (RVO)\n3. Scheduled for intravitreal anti-VEGF injection (bevacizumab, aflibercept, or faricimab)\n4. Able to provide written informed consent\n\nExclusion Criteria:\n\n1. Active ocular infection or inflammation\n2. Known allergy to povidone-iodine, tetracaine, or levofloxacin\n3. Inability to cooperate with the injection procedure\n4. Concurrent participation in another interventional clinical trial\n5. Anatomical eyelid abnormality precluding use of either retraction technique","ALL","18 Years",{"count":20,"type":21},120,"ESTIMATED","INTERVENTIONAL",[24],"NA","This randomized controlled trial compares two techniques for eyelid retraction during intravitreal injection (IVI) of anti-VEGF agents: the standard wire eyelid speculum (Group A) versus cotton-tipped applicator retraction (Group B) in patients with neovascular AMD, diabetic macular edema, or retinal vein occlusion.\n\nThe study evaluates four outcomes: (1) patient pain perception measured by a 10-cm visual analogue scale immediately after injection; (2) procedure duration from retraction device placement to removal; (3) patient satisfaction assessed by a 5-item Likert scale; and (4) safety including rates of subconjunctival hemorrhage, corneal abrasion, endophthalmitis, and intraocular pressure elevation.\n\nA novel syringe cap technique using the Terumo 31G insulin syringe plastic cap as an injection-site marker (3.5 mm for pseudophakic eyes, 5.0 mm for phakic eyes from the limbus) is employed in both groups, replacing the traditional caliper.\n\nRandomization is stratified by diagnosis and prior injection history using permuted block randomization (block sizes 4 and 6). The target sample size is 120 patients (60 per group) at Walailak University Hospital, Nakhon Si Thammarat, Thailand.",[27,28,29,30],"Neovascular Age-Related Macular Degeneration (nAMD)","Diabetic Macular Edema","Retinal Vein Occlusion","Intravitreal Injections",[32,33,34,35,36,37,38,39],"intravitreal injection","eyelid speculum","cotton-tipped applicator","injection pain","procedure time","patient satisfaction","anti-VEGF","randomized controlled trial","NOT_YET_RECRUITING","2026-03-13",{"date":43,"type":44},"2026-03-18","ACTUAL",{"date":46,"type":21},"2026-06",{"date":48,"type":21},"2027-08",{"name":50,"class":51},"Jakkrit Juhong","OTHER",{"id":53,"slug":54,"hasResults":11,"nctId":55,"briefTitle":56,"officialTitle":57,"acronym":58,"eligibilityCriteria":59,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":60,"targetDuration":4,"studyType":62,"phases":4,"briefSummary":63,"conditions":64,"keywords":65,"overallStatus":71,"whyStopped":4,"lastUpdateSubmitDate":72,"lastUpdatePostDateStruct":73,"startDateStruct":75,"completionDateStruct":77,"leadSponsor":79,"locationsCount":81},"100578339","eye-diseases-treated-with-interoperable-medical-informatics-100578339","NCT06810011","Eye Diseases \"Treated\" With Interoperable Medical Informatics","EyeMatics - Eye Diseases \"Treated\" With Interoperable Medical Informatics","EyeMatics","Inclusion Criteria:\n\n* OPS code: \"5-156.9 Injection of drugs into the posterior segment of the eye\"",{"count":61,"type":21},2000,"OBSERVATIONAL","The overarching goal of EyeMatics is to promote an interoperable, sustainable infrastructure for the integration and sharing of data from clinical research to improve personalized medicine in ophthalmology. To achieve this, EyeMatics bundles the expertise and preliminary work of the four consortia of the Medical Informatics Initiative (MII) and the ophthalmological centers of excellence in Germany. The perspective and concerns of patients will be strongly incorporated into the project work through close cooperation with patient representatives and the inclusion of patient feedback on quality of life and treatment success.\n\nEyeMatics aims to improve the understanding of the therapeutic success of eye diseases that are usually treated with intravitreal surgical medication (IVOM). To this end, an exemplary analysis platform for \"real\" clinical data will be provided and a dashboard for data visualization and analysis will be developed as a web application. The dashboard is to be introduced at all participating hospital sites for research purposes.",[30],[66,67,68,69,70],"Artificial intelligence","Core dataset","Intraviteal Injection","Medical Informatics","Data exchange","RECRUITING","2025-01-30",{"date":74,"type":44},"2025-02-05",{"date":76,"type":44},"2024-03-01",{"date":78,"type":21},"2028-02-29",{"name":80,"class":51},"University Hospital Muenster",6,{"id":83,"slug":84,"hasResults":11,"nctId":85,"briefTitle":86,"officialTitle":87,"acronym":88,"eligibilityCriteria":89,"healthyVolunteers":11,"sex":17,"minAge":90,"maxAge":4,"enrollmentInfo":91,"targetDuration":4,"studyType":62,"phases":4,"briefSummary":93,"conditions":94,"keywords":4,"overallStatus":71,"whyStopped":4,"lastUpdateSubmitDate":96,"lastUpdatePostDateStruct":97,"startDateStruct":99,"completionDateStruct":101,"leadSponsor":103,"locationsCount":105},"100260476","aflibercept-in-recurrent-or-persistent-cnv-100260476","NCT02669953","Aflibercept in Recurrent or Persistent CNV","Response to Aflibercept After Previous Intravitreal Ranibizumab Treatment in Neovascular Age-Related Macular Degeneration","OPHTH-010915","Inclusion Criteria:\n\nAdults ≥ 50 years\n\n* Patients who have been treated with ranibizumab due to wet age-related macular degeneration for up to one year\n* BCVA \\>= 20\u002F400 in the study eye using ETDRS\n* Willingness and ability to comply with regular visits\n* Signed informed consent\n\nExclusion Criteria:\n\n* Any surgical treatment of the eye within 3 months prior to baseline in the study eye\n* History of uncontrolled glaucoma in the study eye (defined as intraocular pressure ≥ 25 mmHg despite treatment with anti-glaucoma mediation)\n* Aphakia or absence of the posterior capsule (excluding YAG-capsulotomy) in the study eye\n* Retinal pigment epithelial tear involving the macula in the study eye","50 Years",{"count":92,"type":21},80,"Age-related macular degeneration (AMD) and diabetic retinopathy are among the most common disorders causing visual disability in elderly people. AMD leads to dysfunction and loss of photoreceptors in the central retina. Neovascular AMD (nAMD) affects visual function early in the disease process.\n\nThe purpose of the study is to evaluate the effect of switching from ranibizumab therapy to the current routine therapy using aflibercept in eyes with treatment naive, recurrent or persistent nAMD, treatment naive diabetic retinopathy and pretreated diabetic retinopathy.\n\n20 patients with recurrent or persistent nAMD, previously treated with intravitreal ranibizumab for up to one year will be included in this trial. Patients will be examined in monthly intervals over 12 months follow-up.\n\nExaminations carried out will include: Best-corrected visual acuity (BCVA) using ETDRS charts at 4m distance, Reading Performance (RP), Standard ophthalmic examinations (SOE incl. funduscopy and applanation tonometry), Optical coherence tomography (OCT), Autofluorescence fundus image (AF) \\& red-free autofluorescence fundus image (RF), Color fundus photography (CFP), Fluorescein angiography and indocyaningreen angiography (FLA\u002FICG), Microperimetry (MP), as well as Non-invasive OCT based optical angiography (AngioVue).",[95,30,28],"Age Related Macular Degeneration","2024-11-22",{"date":98,"type":44},"2024-11-26",{"date":100,"type":4},"2015-12",{"date":102,"type":21},"2025-12",{"name":104,"class":51},"Medical University of Vienna",1]